Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 5/20 | 0.39 |
| ▸ | THRB | P10828 | 9/20 | 0.38 |
| ▸ | THRA | P10827 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459710 | 0.87 | THRB (0.40) | P2RX7ABCB11PLATTHRBTHRA | |
| Hydrochloric Acid SCHEMBL6461599 | 0.85 | THRB (0.39) | P2RX7ABCB11PLATTHRBTHRA | |
| SCHEMBL6454313 | 0.85 | THRB (0.40) | P2RX7ABCB11PLATTHRBTHRA | |
| SCHEMBL6455277 | 0.83 | THRB (0.38) | P2RX7ABCB11PLATTHRBTHRA | |
| SCHEMBL6459165 | 0.81 | MEN1 (0.40) | P2RX7ABCB11PLATTHRBTHRA | |
| SCHEMBL6465988 | 0.80 | HPGD (0.43) | P2RX7ABCB11THRBTHRAMEN1 | |
| SCHEMBL7705453 | 0.76 | MEN1 (0.36) | P2RX7ABCB11PLATTHRBTHRA | |
| SCHEMBL7139293 | 0.72 | THRA (0.42) | PLATTHRBTHRAMEN1KMT2A | |
| SCHEMBL6453803 | 0.72 | P2RX7 (0.39) | P2RX7ABCB11THRBTHRAMEN1 | |
| SCHEMBL5761739 | 0.71 | THRA (0.41) | PLATTHRBTHRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206471-B1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-01 | — | — | EP | disclosed |
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6894046-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-17 | — | — | US | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1114046-B1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN CILAG S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
| EP-0987265-A1 | Interleukin-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | ALOX5, IL5, IL6ST | P2RX7 880/4885ABCB11 2670/4885PLAT 4210/4885 |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | P2RX7 545/4885ABCB11 2943/4885PLAT 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.